Danisco to produce natural, biological preservative

Related tags Middle east Denmark Danisco

Danish ingredients company Danisco announced this week that it is
use new production facilities in Denmark to produce Natamax - a
natural, biological preservative.

Danish ingredients company Danisco announced this week that it is to use new production facilities in Denmark to produce Natamax - a natural, biological preservative.

The new facilities, worth around DKK 90 million (€12.1m), have just been commissioned at the Grindsted site and are dedicated to the production of Natamax, which is a biological protectant used by the global food industry.

Danisco has held the rights to Natamax, originally developed by Pfizer, for the past five years. Up until now, the ingredient was produced at a Pfizer plant in the USA. Natamax, produced on the basis of fermentation, is used in foods. In the dairy industry, it is used for surface treatment of cheese products to prevent formation of mould. It is also used in dried sausages and in fruit juice to control yeast and mould, which can spoil foods and in extreme cases develop hazardous toxins.

According to the company, the Natamax product is doing well in USA, Mexico, South America and Europe and is growing in popularity in the Middle East and Asia - countries with warm climates .

Danisco has chosen to place the production of Natamax in Denmark due to the Grindsted site's extensive fermentation know-how. Where fermentation normally takes 24-48 hours, the fermentation process involved in the production of Natamax takes 11 days (24 hours a day).

Related news

Related products

show more

Whitepaper: Discover a new era in postbiotics

Whitepaper: Discover a new era in postbiotics

Content provided by DSM Nutritional Products | 28-Nov-2023 | White Paper

Postbiotic ingredients are set to open up a world of opportunities across the human health and nutrition industry, fueled by developing science demonstrating...

Taking Immune Support to a New Level

Taking Immune Support to a New Level

Content provided by AB Biotek Human Nutrition & Health | 30-Oct-2023 | White Paper

Patent-pending ABB C1® redefines immune support by addressing innate, acquired, and Trained Immunity. In 'ABB C1®: Training Now for Future Immune...

Related suppliers

Follow us

Products

View more

Webinars